Ascendis Pharma Introduces Vision 2030
Strategic roadmap to achieve blockbuster status for multiple products and expandthe Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, […]
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue
SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing […]
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year […]
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data […]
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients […]
QIAGEN gibt Pläne zur Rückzahlung von rund $300 Mio. an Aktionärinnen und Aktionäre bekannt
Kapitalrückzahlung durch synthetischen Aktienrückkauf // Rückzahlung von bis zu $300 Mio. – von Aktionärinnen und Aktionären im Jahr 2023 genehmigter […]
QIAGEN announces plans to return approximately $300 million to shareholders
Venlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a […]
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today […]
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
— Tim Kelly to lead Caribou’s technical operations strategy and execution — — CB-010 ANTLER Phase 1 trial initial dose […]
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue […]
